[Generalized neonatal screening based on laboratory tests]

Area of Science:

• Public Health
• Genetics
• Pediatrics

Context:

• Neonatal screening programs are essential for early detection of severe childhood diseases.
• France has a national program screening for phenylketonuria, hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, and sickle cell disease.
• Technological advancements enable screening for numerous diseases, raising organizational and ethical questions.

Purpose:

• To outline the criteria for implementing generalized neonatal disease screening programs.
• To discuss the current state and challenges of neonatal screening in France.
• To address ethical considerations and suggest improvements for future screening initiatives.

Summary:

• Neonatal screening programs must adhere to strict guidelines regarding disease severity, early detection, effective treatment, and public health impact.
• Current French programs include phenylketonuria, hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, and sickle cell disease, with ongoing discussions for expansion.
• Ethical dilemmas arise with increased screening capabilities, particularly concerning incurable or late-onset diseases, necessitating updated guidelines and rigorous evaluation.

Impact:

• Ensures early diagnosis and treatment, improving life expectancy and outcomes for affected children.
• Facilitates prenatal screening and informs heterozygous carriers, aiding family planning and genetic counseling.
• Promotes continuous improvement of screening programs through local testing, dedicated evaluation committees, and long-term outcome studies.